Logicum | Scientia | Humanitas

Tyme Inc.

Using a Unique Metabolic Approach to Treat Stage IV Metastatic Cancer.

Tyme Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, our therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Our lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and we are preparing to initiate an additional Phase II clinical trial for pancreatic cancer. 

Proprietary and Patented

Tyme’s Novel Approach: SM-88

SM-88 is Investigational and Undergoing Clinical Studies to Evaluate Safety and Effectiveness. It Has Not Been Approved by the FDA.

Tyme’s proprietary and patented SM-88 compound is a combination of unique chemistry and established drugs. SM-88 is designed to penetrate exclusively the living cancer cells and introduce multiple mechanisms to kill the cell without any toxicity or involvement of healthy body tissue. SM-88 may achieve cancer cell death by inducing the transfer of electrons in the cancer cells that allow catalyzed external free radicals to react and stress the cell. The compound could create an engineered metabolic response which may result in the altering of cancer’s cell defenses to oxidative stress. Tyme plans to study whether an SM-88 bolstered immune system can fight the disease to a stability and remission.

Mechanism of Action

SM-88 is Designed to Target Only Active Cancer Cells.

Chemotherapy compounds are toxic, and are designed to interfere with the mechanism of cell division but are not selective, and thus toxic to the organs and the body as a whole. Unlike many toxic chemotherapies, SM-88 is designed to target only active cancer cells and to force them to be vulnerable to the body’s natural defenses and processes.

Participating Institutions

Mayo Clinic
Mount Sinai
Emory Healthcare
MD Anderson Cancer Center
Medical College of Wisconsin
The University of Kansas
SIGN UP TO RECEIVE UPDATES FROM TYMEX


By submitting this form, you are granting: Tyme Inc., 44 Wall Street, New York, NY, 10005, permission to email you. You may unsubscribe via the link found at the bottom of every email. (See our Email Privacy Policy (http://constantcontact.com/legal/privacy-statement) for details.) Emails are serviced by Constant Contact.